Skip to main content
NCBI home page
Acta Clinica Croatica logoLink to Acta Clinica Croatica
. 2018 Sep;57(3):464–472. doi: 10.20471/acc.2018.57.03.09

EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA

Stefan Naydenov Naydenov 1,✉, Nikolay Margaritov Runev 1, Emil Ivanov Manov 1, Svetla Georgieva Torbova-Gigova 2
PMCID: PMC6536285  PMID: 31168179

Abstract

SUMMARY – The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk. This prospective study included 243 patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk, mean age 63.3±9.8 years. All patients were prescribed a treatment with one of the following doses of a single-pill combination of atorvastatin/amlodipine: 10/5, 10/10, 20/5 or 20/10 mg daily. The follow-up period was 3 months. The mean baseline values of the systolic and diastolic blood pressure were 155.7±16.2 and 92.0±9.2 mm Hg, respectively. At month 3, the respective mean systolic and diastolic blood pressure values were 136.9±26.9 and 80.6±5.1 mm Hg. The mean baseline values of total cholesterol and low-density lipoprotein cholesterol were 6.6±1.2 and 4.4±1.1 mmol/L, respectively. At month 3, the respective mean values of total cholesterol and low-density lipoprotein cholesterol were 5.1±0.9 and 2.9±1.0 mmol/L. Treatment was discontinued in 9 (3.7%) patients due to adverse events. In conclusion, treatment with the single-pill combination of atorvastatin/amlodipine was effective and well tolerated by the patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk.

Key words: Hypertension, Dyslipidemias, Cardiovascular diseases, Antihypertensive agents

Introduction

Arterial hypertension (HTN) and dyslipidemias are the most significant risk factors (RF) for cardiovascular (CV) complications worldwide (1-4). HTN affects ~22% of the world population (30%-45% in Europe and North America) and dyslipidemias ~39% of the population aged ≥25 years (54% of the Europeans) (1-5).

In a number of epidemiological studies, elevated blood pressure (BP) and cholesterol have been identified as strong RF for coronary heart disease, cerebrovascular disease, peripheral arterial disease, etc. (6, 7). Regardless of the existing pharmacological and non-pharmacological options, control of these RF is unsatisfactory. At least 50% of patients with HTN and/or hypercholesterolemia in many countries of Europe, North America and Asia maintain BP and/or low-density lipoprotein cholesterol (LDL-C) and/or total cholesterol (TC) levels above the target ones (1, 2, 7). Each year ~8 million hypertensives die and another ~60 million develop severe debilitating complications as a consequence of uncontrolled HTN (5). Another 2.6 million patients with dyslipidemia die yearly and about 30 million are seriously disabled due to untreated or not effectively treated hypercholesterolemia (8).

The contemporary combination antihypertensive and lipid-lowering strategies are based mostly on the level of CV risk of the individual patient on the one hand, and on the BP, LDL-C and TC values (baseline and target ones) on the other hand (5, 8-10). Where possible, single-pill combinations (SPC) are widely recommended because of the certain advantages over free combinations, i.e. standardized dose of the ingredients, facilitated treatment regimen with less tablets and often more affordable price (5, 8, 11). These features improve patient adherence to the prescribed treatment, and thus to HTN and dyslipidemia control (11-13).

The SPC of atorvastatin/amlodipine in various proportions is one the most reasonable options for combination treatment in patients with HTN and hypercholesterolemia. Its pharmacokinetic and pharmacodynamic features, as well as the proven clinical benefits of each of the active components gave us grounds for conducting a prospective clinical study among outpatients (14-16).

Patients and Methods

A prospective, open-label study, conducted from March to August, 2014, included 243 consecutive outpatients with HTN and dyslipidemia (128 (52.7%) males) from 20 Bulgarian cities, towns and villages, mean age 63.3±9.8 (range, 40-91) years. The study conductance was in accordance with ethical standards of the institutional or regional responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. A written informed consent was obtained from all patients before their enrolment in the study and an approval of the study was obtained from the local ethics committee.

Inclusion criteria

The study inclusion criteria were as follows: 1) patients with essential HTN and dyslipidemia (according to the current European guidelines for diagnosis and treatment of these diseases); 2) patients on outpatient antihypertensive and lipid-lowering therapy, not achieving the target BP and/or LDL-C values according to the current European guidelines (5, 8) at ≥1 month of treatment initiation; 3) patients requiring antihypertensive and lipid-lowering therapy according to the current European guidelines, but not receiving medication therapy before inclusion in the study; 4) feasible follow-up in the course of 3 months after initiation of atorvastatin/amlodipine treatment; and 5) an informed consent from the patient to participate in the study.

Exclusion criteria

Exclusion criteria were as follows: 1) known secondary hypertension and/or dyslipidemia; 2) target BP and/or lipid levels achieved by the ongoing therapy; 3) known adverse effects from previous experience or present contraindications to any of the atorvastatin/amlodipine SPC components; 4) patients already on maximal daily dose of amlodipine (10 mg) and/or atorvastatin (80 mg), not achieving the target BP and/or lipid levels; 5) patient’s refusal to be treated with the atorvastatin/amlodipine SPC; and 6) impossibility of patient follow-up in the course of 3 months for whatever reason.

Among all patients, 231 (95.1%) had antihypertensive treatment, but had not achieved the target BP values despite combination therapy with 2 to 3 drugs in most of them (218 of 231, 94.4%). An angiotensin-converting enzyme inhibitor had been included in therapy of 118 (48.6%) patients, a calcium channel blocker was taken by 81 (33.3%), an angiotensin II-receptor blocker by 88 (36.2%), a beta-blocker by 152 (62.6%), a thiazide diuretic by 19 (7.8%), and other BP-lowering drugs by 28 (11.5%) patients. The mean number of antihypertensive tablets received by the hypertensive patients was 3.0±1.5 (0-8): 2 tablets by 48 (22.0%), 3 tablets by 77 (35.3%), 4 tablets by 39 (17.9%) and 5 tablets by 25 (10.3%) patients.

Sixty-seven (27.6%) patients had been on statin treatment before inclusion in the study, and 31 (46.3%) of them had received atorvastatin.

All patients were evaluated for CV risk. The Systematic COronary Risk Evaluation (SCORE) model (5, 8) was used to assess the absolute 10-year risk of fatal cardiac event in asymptomatic patients with cardiovascular RF. The added CV risk was assessed in hypertensives with RF and/or subclinical target organ damage or overt CV or non-cardiac complications. The risk was found to be moderate in 70 (39.3%) and high in 173 (59.7%) patients.

All patients enrolled in our study started treatment with one of the following doses of the SPC atorvastatin/amlodipine (Gedeon Richter Plc., Hungary): 10/5, 10/10, 20/5 or 20/10 mg daily with up-titration at visit 1 when necessary. The dosage was determined by the treating physician based on the BP and LDL-C values and the level of individual CV risk as well.

The concomitant medication was continued unless it was a calcium channel blocker or statin. The period of patient follow-up was 3 months with clinical visits at the end of months 1 and 3 after initiation of SPC atorvastatin/amlodipine treatment. At baseline and at each follow-up visit, office BP measurement was performed after 10-min rest in sitting position, twice at the non-dominant arm with 1-min interval between the measurements. During follow-up visits, detailed medical history was taken about treatment regimen, home BP control and presence of adverse effects (AE). In patients not achieving the target BP and/or LDL-C levels recommended by the current Guidelines of the European Society of Cardiology, an increase in the dose of the researched combination was considered.

At baseline and at month 3, the following lipid parameters were examined: TC, LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG).

Statistics

Statistical analysis was carried out with SPSS statistical package, version 16.0 (SPSS Inc, Chicago, IL, USA). Data were expressed by frequencies and percentages for categorical variables, and by minimal, maximal, mean values and standard deviation for continuous variables. Comparisons were made by using the independent χ2-test, t-test, and ANOVA. The level of statistical significance was set at p<0.05.

Results

Figure 1 shows the prescription rate of the analyzed 4 dose combinations of atorvastatin/amlodipine at baseline, month 1 and month 3.

Fig. 1.

Fig. 1

Open in a new tab

Prescription of different atorvastatin/amlodipine combinations to study population at baseline, month 1 and month 3. 10/5 mg: p=0.03 for baseline vs. month 1 and month 3; p=NS for month 1 vs. month 3; 10/10 mg: p=0.01 for baseline vs. month 1 and p=0.04 vs. month 3, p=0.03 for month 1 vs. month 3; 20/5 mg: p<0.0001 for baseline vs. month 1 and month 3; p=NS for month 1 vs. month 3; 20/10 mg: p=0.02 for baseline vs. month 1 and month 3; p=NS for month 1 vs. month 3. NS = nonsignificant; p = level of statistical significance

The mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) values of the analyzed group of patients at baseline and at the end of month 1 and 3 are shown in Table 1, whereas Figure 2 illustrates the dynamics of BP during the follow-up period.

Table 1. Systolic and diastolic blood pressure values in study population at baseline and at follow-up visits during the treatment period.

    Blood pressure     Minimal
    value
    (mm Hg)		     Maximal
    value
    (mm Hg)		     Mean
    value
    (mm Hg)		     Standard
    deviation
    Baseline SBP     146     200     155.67     16.21
    Baseline DBP     90     118     92.03     9.23
    SBP – month 1     107     183     140.69     13.59
    DBP – month 1     70     105     83.41     6.32
    SBP – month 3     112     148     136.88     26.97
    DBP – month 3     65     90     80.64     5.07
Open in a new tab

DBP = diastolic blood pressure; SBP = systolic blood pressure

Fig. 2.

Fig. 2

Open in a new tab

Dynamics of systolic and diastolic blood pressure in study population after initiation of treatment with atorvastatin/amlodipine. DBP = diastolic blood pressure; SBP = systolic blood pressure; NS = nonsignificant; p = level of statistical significance

The normalization rate of BP, defined for our study as SBP <140 and DBP <90 mm Hg (<85 mm Hg for diabetic patients) in accordance with the current 2013 ESC Guidelines for treatment of arterial hypertension (5) was as follows:

  • at month 1: SPB <140 mm Hg was achieved by 147 (60.5%) and DBP <90 mm Hg by 183 (75.3%) patients; p<0.0001 vs. baseline;

  • at month 3: SPB <140 mm Hg was achieved by 175 (72.1%) and DBP <90 mm Hg by 221 (91.0%) patients; p<0.0001 vs. baseline and month 1.

The mean SBP and DBP values of patients treated with the most frequently prescribed dosage of 10/5 mg of the SPC of atorvastatin/amlodipine are shown in Table 2, whereas Figure 3 illustrates the dynamics of their BP during the follow-up period.

Table 2. Systolic and diastolic blood pressure values in study patients treated with the lowest dose of atorvastatin/amlodipine (10/5 mg).

    Blood pressure     Minimal
    value
    (mm Hg)		     Maximal
    value
    (mm Hg)		     Mean
    value
    (mm Hg)		     Standard
    deviation
    Baseline SBP     146     197     153.17     15.03
    Baseline DBP     90     110     90.81     9.02
    SBP – month 1     108     182     138.55     12.80
    DBP – month 1     70     95     82.71     5.59
    SBP – month 3     116     167     130.36     12.99
    DBP – month 3     65     90     80.59     5.47
Open in a new tab

DBP = diastolic blood pressure; SBP = systolic blood pressure

Fig. 3.

Fig. 3

Open in a new tab

Dynamics of systolic and diastolic blood pressure in patients treated with 10/5 mg atorvastatin/amlodipine. DBP = diastolic blood pressure; SBP = systolic blood pressure; p = level of statistical significance

The normalization rate of BP of the patients treated with atorvastatin/amlodipine 10/5 mg was as follows:

  • at month 1: SPB <140 mm Hg was achieved by 64 (45.7%) and DBP <90 mm Hg by 116 (82.6%) patients; p<0.0001 vs. baseline;

  • at month 3: SPB <140 mm Hg was achieved by 108 (76.9%) and DBP <90 mm Hg by 127 (90.6%) patients, p<0.0001 vs. baseline and month 1.

The mean values of the lipid parameters at baseline and at month 3 are shown in Table 3, whereas the dynamics of TC and LDL-C are illustrated in Figure 4.

Table 3. Values of lipid parameters in study population.

    Lipid parameter
    (mmol/L)		     Minimal value     Maximal value     Mean value     Standard
    deviation
    Baseline TC     5.4     10.3     6.6     1.2
    Baseline LDL-C     3.5     7.9     4.4     1.1
    Baseline HDL-C     0.5     2.2     1.3     0.5
    Baseline TG     0.6     6.0     2.1     0.8
    TC – month 3     2.9     6.4     5.1     0.9
    LDL-C – month 3     0.8     4.6     2.9     1.0
    HDL-C – month 3     0.8     2.5     1.4     0.5
    TG – month 3     0.6     4.6     1.6     0.7
Open in a new tab

HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; TG = triglycerides

Fig. 4.

Fig. 4

Open in a new tab

Dynamics of total cholesterol and low-density lipoprotein cholesterol in study population. TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol; p = level of statistical significance

Target values of the analyzed lipid parameters (according to the recommendations of the current ESC Guidelines for cardiovascular prevention) (8) were achieved at month 3 as follows:

  • patients at moderate CV risk: LDL-C <3.0 mmol/L in 52 (74.3%) and TC <5.0 mmol/L in 55 (78.6%) patients; p<0.0001 vs. baseline;

  • patients at high CV risk: LDL-C <2.5 mmol/L in 108 (62.4%) and TC values <4.5 mmol/L in 114 (65.9%) patients; p<0.0001 vs. baseline.

The values of lipid parameters in patients treated with the most frequently prescribed dosage of 10/5 mg of the SPC of atorvastatin/amlodipine are shown in Table 4, whereas Figure 5 shows the dynamics of TC and LDL-C.

Table 4. Values of lipid parameters in patients treated with the lowest dose of atorvastatin/amlodipine (10/5 mg).

    Lipid parameter
    (mmol/L)		     Minimal value     Maximal value     Mean value     Standard
    deviation
    Baseline TC     5.4     9.7     6.3     1.2
    Baseline LDL-C     3.5     7.9     4.3     1.2
    Baseline HDL-C     0.5     1.9     1.3     0.4
    Baseline TG     0.6     3.5     1.9     0.7
    TC – month 3     3.3     6.4     5.2     1.0
    LDL-C – month 3     1.0     5.7     3.1     1.0
    HDL-C – month 3     0.8     2.1     1.3     0.4
    TG – month 3     0.6     4.4     1.7     0.7
Open in a new tab

HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; TG = triglycerides

Fig. 5.

Fig. 5

Open in a new tab

Dynamics of total cholesterol and low-density lipoprotein cholesterol in patients treated with 10/5 mg atorvastatin/amlodipine. TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol; p = level of statistical significance

Treatment with the lowest dose of 10/5 mg of the SPC of atorvastatin/amlodipine achieved target values of the analyzed lipid parameters at month 3 as follows:

  • patients at moderate CV risk: LDL-C values <3.0 mmol/L in 37 (63.8%) and TC values <5.0 mmol/L in 39 (67.2%) patients; p<0.0001 vs. baseline;

  • patients at high CV risk: LDL-C <2.5 mmol/L in 24 (38.7%) and TC values <4.5 mmol/L in 28 (45.2%) patients; p<0.0001 vs. baseline.

On clinical visits at months 1 and 3, we recorded the following adverse events (AE) that could be attributed to the treatment with the SPC of atorvastatin/amlodipine:

  • mild to moderate facial flush: 2 (1.1%) patients at month 1 and 1 (0.6%) patient at month 3;

  • mild to moderate swelling edema of lower extremities: 6 (3.4%) patients at month 1 and month 3 each;

  • mild to moderate headache: 3 (1.7%) patients at month 1, whereas none of the patients complained of headache at month 3;

  • mild to moderate myalgia: 2 (1.1%) patients at month 1 and month 3 each.

Treatment with the investigated SPC of atorvastatin/amlodipine was discontinued in nine (3.7%) patients because of AE (swelling edema and/or headache); three of them stopped treatment at week 2, four patients at month 1 and two patients at month 2.

Discussion

In our study, treatment of patients with the SPC of atorvastatin and amlodipine led to significant reduction of both blood pressure and LDL-C as important indicators of CV risk. The mean reduction of BP across all dose regimens used (from 10/5 mg to 20/10 mg) was ~12% for SBP and DBP each. The percentage of patients achieving the target BP values at the end of the study was high (72.1% and 91.0% for SBP and DBP, respectively).

Our results were comparable to those published by Kékes (17). In their study, 2606 patients with HTN and dyslipidemia were treated with an SPC of atorvastatin and amlodipine. All dosage regimens from 10/5 to 20/10 mg were analyzed. The mean baseline SBP and DBP values were 155.9 and 90.2 mm Hg and they were reduced at month 3 to 136.9 and 83.6 mm Hg, respectively. At the end of the study, 86.5% of the patients reached the target BP levels (<140/90 mm Hg) (17).

In our study, the analyzed SPCs also demonstrated a statistically significant lipid-lowering effect; the values of TC and LDL-C were reduced by ~23% and 34%, respectively, compared to baseline values. In the study performed by Kékes et al., LDL-cholesterol was reduced from the mean value of 3.45 mmol/L to 2.49 mmol/L after 3 months of treatment and 76.4% of the patients reached the target LDL-C levels at the end of the study (17).

In more than half of our patients, the lowest dosage of the SPC of atorvastatin/amlodipine was prescribed at inclusion in the study (individual decision of the treating physician) and this regimen was maintained until the end of the study in 49% of patients. This dosage achieved 15% additional SBP and 11% DBP reduction when added to the ongoing antihypertensive therapy. The mean reduction of the analyzed lipid parameters by this dosage of atorvastatin/amlodipine was by ~18% for TC and by ~28% for LDL-C. Reduction of LDL-C <3.0 mmol/L was achieved by 46.5% of the patients treated with the 10/5 mg SPC of atorvastatin/amlodipine. It means that the low-dose combination of atorvastatin/amlodipine could be a reasonable choice for a large number of patients with moderate to high CV risk and mild to moderate elevation of BP and LDL-C.

Our results could also be compared with the results from several other studies. In the Gemini Study (1220 patients with uncontrolled HTN and dyslipidemia included), eight dosage regimens of an SPC of amlodipine/atorvastatin (from 5/10 to 10/80 mg) were electively titrated to improve blood pressure and lipid control (18). At baseline, the mean BP was 146.6/87.9 mm Hg and mean LDL-C was 152.9 mg/dL. At the end of the study, 57.7% of patients achieved both their BP and LDL-C goals. The mean dose of the study medication at the end point was amlodipine component 7.1 mg and atorvastatin component 26.2 mg (18).

In the CAPABLE clinical trial (499 patients with HTN and dyslipidemia included), the SPC of amlodipine/atorvastatin was also administered in one of the 8 dosage regimens available (from 5/10 to 10/80 mg), with the dose being titrated according to the intermediate results (19). At the end point, 48.3% of patients reached both their BP and LDL-C goals; 56.8% reached BP goals and 73.7% reached LDL-C goals (19).

Two other open-label studies conducted in 122 study centers across the United Kingdom and Canada (JEWEL 1) and 113 centers across 11 European countries (JEWEL 2) evaluated the clinical utility of the SPC of amlodipine plus atorvastatin to help patients across Europe and Canada achieve country-specific targets for BP and LDL-C (20). The treatment period was 16 weeks. Among 2245 patients enrolled in these studies, 62.9% in JEWEL 1 and 50.6% in JEWEL 2 reached both country-specific BP and LDL-C goals. BP was reduced by 20.4/10.7 and 21.8/12.6 mm Hg in JEWEL 1 and JEWEL 2, respectively, and reductions in LDL-C were 0.90 mmol/L and 1.09 mmol/L, respectively (20).

Our results and the reports of other clinical studies presented above are quite important. Epidemiologic data have suggested that, on average, less than 10% of patients with concomitant hypertension and dyslipidemia are at target levels for both conditions (7, 21). The large benefits that can result from simultaneous treatment of hypertension and dyslipidemia and the current suboptimal management of these conditions worldwide demonstrate that novel solutions are needed to treat the growing number of patients who have both of these important CV risk factors. The SPC of amlodipine/atorvastatin therapy represents such a solution. Usage of single-pill combinations is associated with 24% lower risk of the lack of compliance to treatment (22). A retrospective cohort study in a large managed-care population (n=8406) showed that patients who initiated therapy with both antihypertensive and lipid-lowering drugs within 30 days apart were more likely to be adherent to both drug regimens over time (23, 24). It has been proven that the high level of patient compliance to treatment is related to 50% reduction of CV events (24, 25).

Treatment with the SPC of atorvastatin/amlodipine was generally well tolerated by our patients. Only nine of 243 (3.7%) patients discontinued treatment, mostly for AE which were relatively rare, mildly to moderately manifested, and often transient. Swelling of lower extremities was the most common one, but compared to other studies with amlodipine its frequency was lower (18-20, 26-28). In the Gemini study, 4.8% of patients discontinued therapy due to AE (18, 26). In JEWEL 1 and 2 studies, the most common ones were peripheral edema (11.0%), joint swelling (2.9%) and headache (2.9%), but only edema was linked to study treatment (20). Similarly, in the CAPABLE clinical trial including 499 patients receiving drug therapy, common treatment-related AE were peripheral edema (3.4%) and headache (2.2%), rarely myalgia and constipation (2.0%) (19).

It could be suggested that the lower rate of AE in our study was because of the use of amlodipine 5 mg in the vast majority of patients (78.6%), as well as the concomitant treatment with angiotensin-converting enzyme inhibitor or angiotensin II-receptor blocker (up to 84.8%).

The main limitations of our study were as follows: 1) our research was designed as a prospective but not randomized and blinded study; 2) control group was not included – the effectiveness of the study medication was not compared to a placebo and/or other drug combination (free or SPC); and 3) the follow-up period was 3 months and conclusions on long-term efficacy and safety of the investigated SPC of atorvastatin/amlodipine could not be drawn.

In conclusion, treatment with the SPC of atorvastatin/amlodipine in our study was effective in reducing both blood pressure and lipid levels and generally well tolerated by patients with moderate to high risk.

References

  • 1.Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. 10.1016/S0140-6736(12)61728-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–60. 10.1016/S0140-6736(02)11403-6 [DOI] [PubMed] [Google Scholar]
  • 3.Naydenov S, Torbova S, Nikolov F, Naydenova N. Abdominal obesity, arterial hypertension and diabetes mellitus in Bulgarian urban population. Bulg J Cardiol. 2013;2:15-24. doi: http://bulgarianjournalofcardiology.blogspot.bg/p/blog-page_3.html.
  • 4.Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens. 2011;29:1641–8. 10.1097/HJH.0b013e328348efa7 [DOI] [PubMed] [Google Scholar]
  • 5.Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357. 10.1097/01.hjh.0000431740.32696.cc [DOI] [PubMed] [Google Scholar]
  • 6.Chalmers J, Arima H, Harrap S, Touyz RM, Park JB. Global survey of current practice in management of hypertension as reported by societies affiliated with the International Society of Hypertension. J Hypertens. 2013;31:1043–8. 10.1097/HJH.0b013e32835f7eef [DOI] [PubMed] [Google Scholar]
  • 7.Devabhaktuni M, Bangalore S. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag. 2009;5:377–87. 10.2147/VHRM.S3339 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Piepoli MF, Hoes A, Agewall S, Albus Ch, Brotons C, Catapano A, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–81. 10.1093/eurheartj/ehw106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Blaha MJ. The critical importance of risk score calibration. Time for transformative approach to risk score validation? J Am Coll Cardiol. 2016;67:2131–4. 10.1016/j.jacc.2016.03.479 [DOI] [PubMed] [Google Scholar]
  • 10.Zeng R, Wang M, Zhang L. Is time an important problem in management of hypertension and hypercholesterolemia by using an amlodipine-atorvastatin single pill combination? Med Sci Monit. 2016;22:2648–55. 10.12659/MSM.896843 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Gadzhanova S, Roughead E, Bartlett L. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia. Eur J Clin Pharmacol. 2016;72:765–71. 10.1007/s00228-016-2037-x [DOI] [PubMed] [Google Scholar]
  • 12.Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller W, et al. Medication adherence and persistence according to different antihypertensive drug classes: a retrospective cohort study of 255,500 patients. Int J Cardiol. 2016;220:668–76. 10.1016/j.ijcard.2016.06.263 [DOI] [PubMed] [Google Scholar]
  • 13.Chapman RH, Benner J, Petrilla A, Tierce J, Collins S, Battleman D, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–52. 10.1001/archinte.165.10.1147 [DOI] [PubMed] [Google Scholar]
  • 14.Deedwania PC, Shepherd J, Breazna A, DeMicco D. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study. Diabetes Obes Metab. 2016;18:56–63. 10.1111/dom.12581 [DOI] [PubMed] [Google Scholar]
  • 15.Mason R. A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:489-501. doi: https://www.ncbi.nlm.nih.gov/pubmed/16503869. [DOI] [PubMed]
  • 16.Paz MA, De La Sierra A, Saez M, Barceló M, Rodríguez J, Castro S, et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore). 2016;95:e4071. 10.1097/MD.0000000000004071 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kékes E. Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk. Orv Hetil. 2008;149:1827–37. 10.1556/OH.2008.28457 [DOI] [PubMed] [Google Scholar]
  • 18.Blank R, La Salle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the Amlodipine/Atorvastatin Gemini Study). J Clin Hypertens (Greenwich). 2005;7:264–73. 10.1111/j.1524-6175.2005.04533.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Flack JM, Victor R, Watson K, Ferdinand K, Saunders E, Tarasenko L, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008;83:35–45. 10.4065/83.1.35 [DOI] [PubMed] [Google Scholar]
  • 20.Hobbs FD, Gensini G, Mancini G, Manolis A, Bauer B, Böhler S, et al. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Int J Cardiol. 2006;110:242–50. 10.1016/j.ijcard.2005.10.017 [DOI] [PubMed] [Google Scholar]
  • 21.Naydenov SN, Runev NM, Manov EI, Shabani RA, Donova TI. Lipid-lowering potency and tolerability of generic rosuvastatin in Bulgarian patients with high and very high risk. J Cardiovasc Dis Diagn. 2014;2:162–7. 10.4172/2329-9517.1000162 [DOI] [Google Scholar]
  • 22.Bašić Kes V, Jurašić M, Zavoreo I, Lisak M, Jeleč V, Matovina L. Age and gender differences in acute stroke hospital patients. Acta Clin Croat. 2016;55:69–78. 10.20471/acc.2016.55.01.11 [DOI] [PubMed] [Google Scholar]
  • 23.Ettehad D, Emdin C, Kiran A, Anderson S, Callender Th, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67. 10.1016/S0140-6736(15)01225-8 [DOI] [PubMed] [Google Scholar]
  • 24.Leibovitz E, Beniashvili M, Zimlichman R, Freiman A, Shargorodsky M, Gavish D. Treatments with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens. 2003;16:715-8. doi: https://www.ncbi.nlm.nih.gov/pubmed/12944027. [DOI] [PubMed]
  • 25.Bangalore S, Kamalakkannan G, Parkar S, Messerli F. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–9. 10.1016/j.amjmed.2006.08.033 [DOI] [PubMed] [Google Scholar]
  • 26.Tomić M, Vrabec R, Poljičanin T, Ljubić S, Duvnjak L. Diabetic macular edema: traditional and novel treatment. Acta Clin Croat. 2017;56:124–32. 10.20471/acc.2017.56.01.18 [DOI] [PubMed] [Google Scholar]
  • 27.Boras V, Andabak-Rogulj A, Brailo V, Šimunković S, Gabrić D, Vrdoljak D. Adverse drug reactions in the oral cavity. Acta Clin Croat. 2015;54:208-15. doi: http://actaclinica.eu/wordpress/wp-content/uploads/2016/08/13-Vucicevic-Acta-2.pdf [PubMed]
  • 28.Preston R, Sun F, Tarasenko L. Safety and tolerability of co-administered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the RESPOND study. Am J Hypertens. 2005;18:92–3. 10.1016/j.amjhyper.2005.03.258 [DOI] [Google Scholar]

Articles from Acta Clinica Croatica are provided here courtesy of Sestre Milosrdnice University Hospital Center

RESOURCES